Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Davalintide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 known ✓ | O60894 | 1/20 | 0.77 |
| ▸ | CALCR known ✓ | P30988 | 1/20 | 0.77 |
| ▸ | CALCRL known ✓ | Q16602 | 1/20 | 0.77 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.77 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.77 |
| ▸ | NPY2R | P49146 | 15/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.66 |
| ▸ | PRLHR | P49683 | 1/20 | 0.64 |
| ▸ | TFPI | P10646 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Davalintide SCHEMBL29377013 | 0.94 | RAMP1 (0.85) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL30078470 | 0.91 | RAMP1 (0.91) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL374892 | 0.89 | RAMP1 (0.78) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Calcitonin Salmon SCHEMBL29392873 | 0.89 | INSR (0.64) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Calcitonin Salmon SCHEMBL269785 | 0.89 | INSR (0.64) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29511605 | 0.89 | RAMP1 (0.71) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Amylin SCHEMBL29351499 | 0.88 | RAMP1 (0.75) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Pramlintide SCHEMBL29355376 | 0.87 | RAMP1 (1.00) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL30888738 | 0.87 | NPY2R (0.63) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29357151 | 0.87 | RAMP1 (0.68) | RAMP1RAMP2RAMP3CALCRCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721760-A1 | COMPOSITION COMPRISING A PEPTIDE HAVING AN ISOELECTRIC POINT OF LESS THAN 6.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | Adocia (FR) | 2026-04-08 | — | — | EP | claimed |
| EP-4684802-A1 | COMPOSITION COMPRISING A PEPTIDE HAVING AN ISOELECTRIC POINT OF LESS THAN 6.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | Adocia (FR) | 2026-01-28 | — | — | EP | claimed |
| WO-2025217521-A1 | TREATING CHRONIC KIDNEY DISEASE WITH A COMBINATION OF A SLC6A19 INHIBITOR AND A GLP-1 AGONIST | JNANA THERAPEUTICS INC. (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4013395-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | Applied Molecular Transport Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| CN-114555058-A | Compositions and particles for payload delivery | 应用分子转运公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2026103453-A1 | LONG-ACTING AMYLIN RECEPTOR AGONIST AND USE THEREOF | 北京志道生物科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026102089-A1 | PRIME DOSE SETTING ASSEMBLY FOR INJECTION DEVICE | ELI LILLY AND COMPANY (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102086-A1 | MEDICATION DELIVERY DEVICE WITH MEDICATION CARTRIDGE AND NEEDLE ASSEMBLY | ELI LILLY AND COMPANY (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122036914-A | Long-acting amylin receptor agonist and application thereof | 北京志道生物科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026088071-A1 | SUBSTITUTED FUSED HETEROARYL LACTAM COMPOUNDS | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4727624-A1 | NEEDLE ASSEMBLY AND FLUID DELIVERY SYSTEM WITH NEEDLE ASSEMBLY | Eli Lilly and Company (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20220380432-A1 | Acylated Calcitonin Mimetics | KEYBIOSCIENCE AG (CH) | 2022-12-01 | — | — | US | disclosed |
| US-11504433-B2 | Cholix-derived carriers for oral delivery of heterologous payload | APPLIED MOLECULAR TRANSPORT INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220288150-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-09-15 | — | — | US | disclosed |
| US-20220275029-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS, INC. | 2022-09-01 | — | — | US | disclosed |
| EP-4013395-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | Applied Molecular Transport Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555058-A | Compositions and particles for payload delivery | 应用分子转运公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220152139-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-05-19 | — | — | US | disclosed |
| US-11324833-B2 | Cholix-derived carriers for oral delivery of heterologous payload | APPLIED MOLECULAR TRANSPORT INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380432-A1 | Acylated Calcitonin Mimetics | CALCA, CALCRL, CALCB | RAMP1 147/4885CALCR 4/4885CALCRL 2/4885 |
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | SLC47A2, SLC47A1, SLC39A14 | RAMP1 3260/4885CALCR 374/4885CALCRL 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.